A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

Fumihiko Kanai,Haruhiko Yoshida,Ryosuke Tateishi,Shinpei Sato,Takao Kawabe,Shuntaro Obi,Yuji Kondo,Makoto Taniguchi,Kazumi Tagawa,Masafumi Ikeda,Chigusa Morizane,Takuji Okusaka,Hitoshi Arioka,Shuichiro Shiina,Masao Omata

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

2011

Fumihiko Kanai
Haruhiko Yoshida
Ryosuke Tateishi
Shinpei Sato
Takao Kawabe
Shuntaro Obi
Yuji Kondo
Makoto Taniguchi
Kazumi Tagawa
Masafumi Ikeda
Chigusa Morizane
Takuji Okusaka
Hitoshi Arioka
Shuichiro Shiina
Masao Omata

Purpose We studied the safety and effectiveness of TSU-68, an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor and fibroblast growth factor receptor, in patients with advanced hepatocellular carcinoma (HCC).

Keywords:

Fibroblast growth factor receptor
Hepatocellular carcinoma
Angiogenesis
Cancer research
Kinase insert domain receptor
Vascular endothelial growth factor
Tyrosine-kinase inhibitor
Pharmacology
Endocrinology
Platelet-derived growth factor receptor
Medicine
Internal medicine
Growth factor receptor
liver function
Tolerability

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations